Zydus Lifesciences has completed the acquisition of Agenus Inc.’s biologics manufacturing facilities and equity stake. The deal includes an exclusive licensing agreement for commercial rights to Botensilimab and Balstilimab in India and Sri Lanka. A new U.S.-based subsidiary, Zylidac Bio LLC, will manage the acquired assets. This positions Zydus in the biologics contract development and manufacturing organization (CDMO) space.
Agenus Acquisition Finalized
Zydus Lifesciences has successfully closed its deal with Agenus Inc., encompassing the acquisition of two U.S.-based biologics manufacturing facilities and a 5.9% equity stake. The agreement was finalized on January 15, 2026.
Zylidac Bio LLC Launched
All acquired manufacturing assets will operate under a newly formed U.S. subsidiary, Zylidac Bio LLC. This enhances Zydus’ global biologics contract development and manufacturing organization (CDMO) business, offering services to biopharmaceutical companies.
Exclusive Licensing Agreement
As part of the deal, Zydus has secured an exclusive licensing agreement for Botensilimab (BOT) and Balstilimab (BAL) in India and Sri Lanka. This grants Zydus commercial rights to Agenus’ lead immuno-oncology assets in these regions.
Strategic Rationale
The acquisition of Agenus’ facilities strengthens Zydus’ manufacturing capabilities and supports its strategy for advancing biosimilars and innovative portfolios. It also addresses the need for secure, domestic manufacturing in the U.S., especially in light of the BIOSECURE Act.
Ventures Arm
Zydus completed its equity investment in Agenus Inc. through its venture capital arm, Zynext Ventures.
Source: BSE
